Skip to main content
Premium Trial:

Request an Annual Quote

Genizon Raises $31M to Support Genome-Wide Association Studies for Metabolic Syndrome

NEW YORK (GenomeWeb News) - Genizon BioSciences said today that it has closed a Series E financing round worth CAD$31 million (US$30.8 million) that it will use to support genome-wide association studies for metabolic syndrome.
BTF, a venture capital fund based in the Netherlands, was the lead investor for the round.
Genizon said the new financing brings its total funding since it was founded in 1999 to more than $130 million.
The company said it will use the new funding to support genome-wide association studies in obesity, type 2 diabetes, dyslipidemia, and hypertension. The company said it will also evaluate links between metabolic syndrome, coronary heart disease, and Alzheimer's disease, and will study genes it has discovered in longevity “that appear to protect against these diseases.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.